(Q54530545)

31 May 2018

title

Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. (English)

1 reference

31 May 2018

0 references

1 reference

1 reference

18

1 reference

31 May 2018

Olivier Hermine

20

1 reference

31 May 2018

Amedée Renand

Amédée Renand

8

0 references

Marie-Olivia Chandesris

Marie-Olivia Chandesris

12

0 references

Patrice Dubreuil

Patrice Dubreuil

19

0 references

Ludovic Lhermitte

2

Ludovic Lhermitte

1 reference

31 May 2018

author name string

Sophie Georgin-Lavialle

1

1 reference

31 May 2018

Felipe Suarez

3

1 reference

31 May 2018

Ying Yang

4

1 reference

31 May 2018

Sébastien Letard

5

1 reference

31 May 2018

Katia Hanssens

6

1 reference

31 May 2018

Frédéric Feger

7

1 reference

31 May 2018

Chantal Brouze

9

1 reference

31 May 2018

Danielle Canioni

10

1 reference

31 May 2018

Vahid Asnafi

11

1 reference

31 May 2018

Achille Aouba

13

1 reference

31 May 2018

Paul Gineste

14

1 reference

31 May 2018

Elizabeth Macintyre

15

1 reference

31 May 2018

Colin D Mansfield

16

1 reference

31 May 2018

Alain Moussy

17

1 reference

31 May 2018

publication date

28 April 2012

1 reference

31 May 2018

European Journal of Haematology

published in

1 reference

31 May 2018

volume

89

1 reference

31 May 2018

issue

1

1 reference

31 May 2018

page(s)

47-52

1 reference

31 May 2018

Bone marrow findings in systemic mastocytosis

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Mast cells and mast cell neoplasia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Classification and diagnosis of mastocytosis: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Diagnostic criteria and classification of mastocytosis: a consensus proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Diagnosis and treatment of systemic mastocytosis: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Advanced mast cell disease: an Italian Hematological Multicenter experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Imatinib for systemic mast-cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Pharmacokinetics of masitinib in cats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Masitinib is safe and effective for the treatment of canine mast cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

Case-control cohort study of patients' perceptions of disability in mastocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01761.X

10.1111/J.1600-0609.2012.01761.X

21 January 2018

Identifiers

DOI

1 reference

31 May 2018

1 reference

31 May 2018